Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rofecoxib

FDA-approved product (tablet, oral), marketed as Vioxx.

Registered studies
32
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Rofecoxib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Rheumatic disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Coxibs
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA33.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

32registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rofecoxib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rofecoxib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

    NCT04684511 · start 2021-06-02

    Registered record
    Registry ID
    NCT04684511
    Conditions
    Hemophilic Arthropathy
    Interventions
    TRM-201 (Rofecoxib); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2021-06-02
    Completion
    2022-09-28
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemophilic Arthropathy
    InterventionTRM-201 (Rofecoxib); Placebo
    PhasePhase 3
    Registry statusTerminated

  • Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial

    NCT00164892 · start 2004-10

    Registered record
    Registry ID
    NCT00164892
    Conditions
    Cancer of Stomach
    Interventions
    Oral Vioxx (Rofecoxib)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2004-10
    Completion
    Not recorded
    Enrolment
    214

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer of Stomach
    InterventionOral Vioxx (Rofecoxib)
    PhasePhase 3
    Registry statusUnknown

  • Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial

    NCT00165048 · start 2004-10

    Registered record
    Registry ID
    NCT00165048
    Conditions
    Cancer of Stomach
    Interventions
    Vioxx (Rofecoxib)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2004-10
    Completion
    Not recorded
    Enrolment
    206

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer of Stomach
    InterventionVioxx (Rofecoxib)
    PhasePhase 3
    Registry statusUnknown

  • An End to the Yom Kippur (and Ramadan) Headache

    NCT00263094 · start 2004-09

    Registered record
    Registry ID
    NCT00263094
    Conditions
    Headache
    Interventions
    Rofecoxib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-09
    Completion
    2004-11
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeadache
    InterventionRofecoxib
    PhaseNot applicable
    Registry statusCompleted

  • 12-Week No-Rofecoxib Plus Aspirin Endoscopy Study (0782-003)

    NCT00543465 · start 2004-08

    Registered record
    Registry ID
    NCT00543465
    Conditions
    Arthritis, Rheumatoid; Osteoarthritis
    Interventions
    MK0782
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2004-08
    Completion
    2004-11
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArthritis, Rheumatoid; Osteoarthritis
    InterventionMK0782
    PhasePhase 2
    Registry statusTerminated

  • A Study of Rofecoxib in the Treatment of Post-Operative Pain After Total Knee Joint Replacement (0966-259)

    NCT00140920 · start 2004-05-25

    Registered record
    Registry ID
    NCT00140920
    Conditions
    Pain
    Interventions
    MK0966; rofecoxib; Comparator: diclofenac 2x 75 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2004-05-25
    Completion
    2004-09-27
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain
    InterventionMK0966; rofecoxib; Comparator: diclofenac 2x 75 mg
    PhasePhase 4
    Registry statusTerminated

  • A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)

    NCT00157872 · start 2004-01-07

    Registered record
    Registry ID
    NCT00157872
    Conditions
    Rheumatoid Arthritis
    Interventions
    MK0966; rofecoxib; Comparator: naproxen tablet 500 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-01-07
    Completion
    2004-09-19
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionMK0966; rofecoxib; Comparator: naproxen tablet 500 mg
    PhasePhase 4
    Registry statusCompleted

  • A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED)

    NCT00092378 · start 2003-09-01

    Registered record
    Registry ID
    NCT00092378
    Conditions
    Postoperative Pain
    Interventions
    MK0966, rofecoxib; Comparator: diclofenac sodium, placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-09-01
    Completion
    2003-12-01
    Enrolment
    251

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Pain
    InterventionMK0966, rofecoxib; Comparator: diclofenac sodium, placebo
    PhasePhase 3
    Registry statusCompleted

  • Coxib-inhibition of Duodenal Polyp Growth in FAP

    NCT00844727 · start 2003-09

    Registered record
    Registry ID
    NCT00844727
    Conditions
    Duodenal Polyposis
    Interventions
    Rofecoxib; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2003-09
    Completion
    2004-04
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDuodenal Polyposis
    InterventionRofecoxib; placebo
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain

    NCT00657449 · start 2003-06-04

    Registered record
    Registry ID
    NCT00657449
    Conditions
    Acute Pain
    Interventions
    valdecoxib; rofecoxib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2003-06-04
    Completion
    2004-10-05
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Pain
    Interventionvaldecoxib; rofecoxib
    PhasePhase 4
    Registry statusTerminated

  • A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)

    NCT00092352 · start 2003-04-29

    Registered record
    Registry ID
    NCT00092352
    Conditions
    Osteoarthritis
    Interventions
    MK0966, rofecoxib; Comparator: celecoxib, placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-04-29
    Completion
    2003-12-01
    Enrolment
    395

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoarthritis
    InterventionMK0966, rofecoxib; Comparator: celecoxib, placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-220)(COMPLETED)

    NCT00092365 · start 2003-04-01

    Registered record
    Registry ID
    NCT00092365
    Conditions
    Osteoarthritis
    Interventions
    MK0966, rofecoxib; Comparator: celecoxib, placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-04-01
    Completion
    2003-11-01
    Enrolment
    413

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoarthritis
    InterventionMK0966, rofecoxib; Comparator: celecoxib, placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate Rofecoxib Versus Placebo and Diclofenac in Patients With Acute Painful Rotator Cuff Syndrome

    NCT00140933 · start 2003-04

    Registered record
    Registry ID
    NCT00140933
    Conditions
    Pain
    Interventions
    MK0966; rofecoxib; Comparator: diclofenac, placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2003-04
    Completion
    Not recorded
    Enrolment
    274

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain
    InterventionMK0966; rofecoxib; Comparator: diclofenac, placebo
    PhasePhase 3
    Registry statusTerminated

  • CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen

    NCT01762891 · start 2003-03

    Registered record
    Registry ID
    NCT01762891
    Conditions
    Antiphospholipid Antibody Syndrome
    Interventions
    Celecoxib; Acetaminophen; Rofecoxib; placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-03
    Completion
    2009-09
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntiphospholipid Antibody Syndrome
    InterventionCelecoxib; Acetaminophen; Rofecoxib; placebo
    PhaseNot applicable
    Registry statusCompleted

  • Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)

    NCT00060476 · start 2003-01-08

    Registered record
    Registry ID
    NCT00060476
    Conditions
    Prostate Cancer
    Interventions
    rofecoxib; Comparator: placebo (unspecified)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-01-08
    Completion
    2004-12-08
    Enrolment
    15,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionrofecoxib; Comparator: placebo (unspecified)
    PhasePhase 3
    Registry statusCompleted